書誌情報
Tip-1. DREAMM-8: Phase 3 Study of Belantamab Mafodotin with Pomalidomide (Pom) + Dexamethasone (Dex) vs Bortezomib + Pom/Dex in Relapsed/Refractory Myeloma
Suzanne Marie Trudel1, Ludek Pour2, Meral Beksac3, Jodie Wilkes4, Ainslee Moore5, Hitomi Kato6, Taku Fujii6, Randy Davis7, Linnette Zhou16, Bikramjit Chopra9, Geraldine Ferron-Brady10, Ira Gupta8, Brandon E. Kremer11, Frank S. Wu8, Vladimir Vorobyev12, Hang Quach13, Sosana Delimpasi14, Meletios A. Dimopoulos15
1Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, 2Department of Internal Medicine, Hematology and Oncology, Masaryk University, 3Department of Hematology, Ankara University, 4Global Clinical Development, GlaxoSmithKline, 5Oncology Global Clinical Development, GlaxoSmithKline, 6Clinical Development, Oncology, GlaxoSmithKline, 7Biostatistics, GlaxoSmithKline, Research Triangle Park, 8Clinical Oncology, GlaxoSmithKline, Upper Providence, 9Pharmacovigilance, GlaxoSmithKline, 10Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, Upper Providence, 11Clinical Development, GlaxoSmithKline, Upper Providence, 12Hematology, S. P. Botkin City Clinical Hospital, 13Clinical Haematology, St Vincent's Hospital, 14Department of Hematology, Evangelismos Hospital, 15Department of Clinical Therapeutics, National and Kapodistrian University of Athens, 16Oncology Clinical Development, GlaxoSmithKline
International Journal of Myeloma 12(3): 115-115, 2022.
個人会員・法人会員の方（IDが5または10で始まる方）
- 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
